Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Zonisamide (AD810; CI912; AD-810; CI-912), an antiepileptic drug, is a voltage-dependent sodium channel and T-type calcium channel blocker. Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures; infantile spasm, mixed seizure types of Lennox–Gastaut syndrome, myoclonic, and generalized tonic clonic seizure. Zonisamide modifies dopamine (DA) activity, provides protection in ischemia mice models and influences antioxidant systems. Zonisamide attenuates the reduction in striatal contents of DA, its metabolite DOPAC and tyrosine hydroxylase (TH).
ln Vitro |
By inhibiting apoptosis, zonisamide (10, 50, 100, and 200 μM; 24 h) improves the viability of SH-SY5Y cells[1]. In PD-cellular models, zonisamide (100 μM; 24 h) promotes neuroprotection. (PD: Parkinson's illness)(1). When proapoptotic molecules are reduced and MnSOD is upregulated (over-expression of MnSOD attenuates MPTP toxicity and shields cells from apoptosis), zonisamide (100 μM; 24 h) is introduced. Heart fibrosis and hypertrophy are inhibited in vitro by zonisamide (0.1, 0.3, 1 μM; 24 h)[3]. When Ang II is applied to NRCMs, zonisamide significantly boosts Hrd1 expression[3].
|
---|---|
ln Vivo |
In the FeCl3-induced chronic amygdalar seizures model, zonisamide (40 mg/kg; ip; once daily for 14 days) inhibits seizures[2]. ?In rats with abdominal aortic constriction (AAC), zonisamide (14, 28, 56 mg/kg; ip; once daily for 6 weeks) reduces cardiac hypertrophy and improves cardiac function[3]. ?In the hearts of AAC rats, zonisamide (14, 28, 56 mg/kg; ip; once daily for six weeks) increases Hrd1 expression and speeds up ERAD[3].
|
Cell Assay |
Cell Viability Assay[1]
Cell Types: SH- SY5Y cells Tested Concentrations: 10, 50, 100, 200 µM Incubation Duration: 24 h Experimental Results: Induced an increase of cell viability, and with the greatest effect being at 100 µM. demonstrated neuroprotective effect on SH-SY5Y cells (PD-cellular models) when at 100 µM. Apoptosis Analysis[1] Cell Types: SH-SY5Y cells Tested Concentrations: 100 µM Incubation Duration: 24 h Experimental Results: demonstrated an effect of anti-apoptotic. RT-PCR[3] Cell Types: NRCMs and cardiac fibroblasts ( expose to Ang II for cardiomyocyte hypertrophy and fibrosis model) Tested Concentrations: 0.1, 0.3, 1 μM Incubation Duration: 24 h Experimental Results: diminished the expression of atrial natriuretic factor (ANF) and cardiomyosin heavy chain β (β-MHC) but increased the expression of cardiac myosin heavy chain α (α-MHC) in NRCMs. diminished cardiac expression of the fibrosis-related gene Collagen 1A1 (Col1A1) in cardiac fibroblasts. Western Blot Analysis[1] Cell Types: SH-SY5Y cells Tested Concentrations: 100 µM Incubation Duration: 24 h Experimental Results: decreased the pr |
Animal Protocol |
Animal/Disease Models: Male Wistar rats (200-250 g; FeCl3-induced chronic amygdalar seizures)[2].
Doses: 40 mg/kg Route of Administration: intraperitoneal (ip)injection; single daily for 14 days. Experimental Results: demonstrated activity of anti-seizures. Dramatically down-regulated GABA transporters GAT-1 in the hippocampus. Animal/Disease Models: Adult male SD (Sprague-Dawley) rats (100-120 g; cardiac hypertrophy model)[3]. Doses: 14, 28, 56 mg/ kg Route of Administration: intraperitoneal (ip)injection; single daily for 6 weeks. Experimental Results: Dramatically attenuated cardiac hypertrophy and fibrosis. Increased LV ejection fraction (EF), fractional shortening (FS) and E/A ratio. Markedly increased the expression of Hrd1 in the hearts of AAC rats. |
References |
[1]. Kawajiri S, et al. Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD. Neurosci Lett. 2010 Sep 6;481(2):88-91.
[2]. Ueda Y, et al. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res. 2003 Aug 19;116(1-2):1-6. [3]. Wu Q, et al. Zonisamide alleviates cardiac hypertrophy in rats by increasing Hrd1 expression and inhibiting endoplasmic reticulum stress. Acta Pharmacol Sin. 2021 Oct;42(10):1587-1597. [4]. De Simone G, et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. |
Molecular Formula |
C8H8N2O3S
|
|
---|---|---|
Molecular Weight |
212.23
|
|
CAS # |
68291-97-4
|
|
Related CAS # |
Zonisamide-d4;1020720-04-0;Zonisamide sodium;68291-98-5
|
|
SMILES |
S(C([H])([H])C1C2=C([H])C([H])=C([H])C([H])=C2ON=1)(N([H])[H])(=O)=O
|
|
InChi Key |
UBQNRHZMVUUOMG-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)
|
|
Chemical Name |
benzo[d]isoxazol-3-ylmethanesulfonamide
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (9.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (9.80 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (9.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 1 mg/mL (4.71 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.7119 mL | 23.5593 mL | 47.1187 mL | |
5 mM | 0.9424 mL | 4.7119 mL | 9.4237 mL | |
10 mM | 0.4712 mL | 2.3559 mL | 4.7119 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.